100% Quality Guarantee
PhD-Level Technical Support
Key Features

Cabiralizumab ELISA Kit (GXEL00084)

SKU GXEL00084
Product Type ELISA Kit
Assay Type Quantitative
Detection Method Colorimetric
Sensitivity 0.156 μg/ml
Range 0.31-5 μg/mL
Size 96T
Synonyms FPA-008, , 1613144-80-1
€880

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

Cabiralizumab ELISA Kit

The Cabiralizumab ELISA Kit (SKU: GXEL00084) is a high-sensitivity quantitative ELISA assay developed for the quantitative measurement of Cabiralizumab in Plasma, Serum. The assay delivers a detection range of 0.31-5 μg/mL and a sensitivity of 0.156 μg/ml and is read colorimetrically at 450 nm, making it well suited to quantitative research workflows.

Cabiralizumab (FPA008) is a humanized monoclonal antibody directed against colony stimulating factor-1 receptor (CSF1R), which is a member of the CSF1/PDGF receptor family of tyrosine-protein kinases. The developers of cabiralizumab including Apexigen, Bristol-Myers Squibb, Five Prime Therapeutics, University of Chicago and Yale University. Although it is reported to be designed for the treatment of tenosynovial giant cell tumor, the studies of treatment for pancreatic cancer, pigmented villonodular synovitis, malignant melanoma, non-small cell lung cancer, renal cell carcinoma and solid tumors also have been reported to be undergoing. The trails of pancreatic cancer and pigmented villonodular synovitis are in Phase II, while others are in Phase I. Orphan designation of cabiralizumab had been granted in the United States and European Commission for the treatment of pigmented villonodular synovitis.

Supplied with pre-coated microplates and all core reagents, the Cabiralizumab ELISA Kit gives you a validated, ready-to-use solution for Cabiralizumab research. Get accurate and reliable results with the Cabiralizumab ELISA Kit from Assay Genie.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose